Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Commensal Cross-Reactive T & B Cells Trigger Autoimmunity

Kurt Ullman  |  October 26, 2020

Dr. Kriegel thinks there is a need to look at both the human genome and microbiome. He says research should begin to identify a subset of individuals who have both genetic risk factors and autoimmunity-inducing bacteria.

“You really can’t easily change the genome, but you can consider a therapy that removes triggers in the microbiome,” he says. “Although no one has started to look closely at R. intestinalis, I think the microbiome adds to the triggers in autoimmunity, suggesting this [field] is a worthwhile area to work on translating to viable therapies.”

Dr. Alexander

Study ‘Thorough & Robust’
Jessy Alexander, PhD, research professor at Department of Medicine, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, N.Y., says this research is a thorough and robust study addressing a novel aspect of the gut microbiome.

“The authors have carried out a detailed study using APS as their focus,” she says. “The unique feature is that they show a microbe that normally inhabits the human gut. R. intestinalis, can generate an immune response and trigger an autoimmune condition.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

β2GPI protein is important in clotting, and antibodies to this protein are present in APS patients. This work revealed a possible mechanism showing that R. intestinalis, closely mimics a cryptic antigen sequence of the β2GPI protein exposed after it is unfolded. When inhibited, the results include fetal loss and thromboembolism.

“Because this is a microbe normally present in the gut, clinicians may not give due importance as one of the possible culprits in APS,” says Dr. Alexander. “The microbial balance and homeostasis are important and should be followed with due diligence in APS and other autoimmune diseases.”


Kurt Ullman is a freelance writer based in Indiana.

Reference

  1. Ruff WE, Dehner C, Kim WJ, et al. Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity. Cell Host Microbe. 2019 Jul 10;26(1):100–113.e8. Epub 2019 Jun 18.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)Hughes SyndromeMicrobiomemicrobiota

Related Articles

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

    February 1, 2014

    With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch

    Studies Find More Evidence the Microbiome Affects Autoimmune Disease

    August 17, 2018

    Evidence is accumulating that the microbiome may be an important part of the pathogenesis of many autoimmune diseases. Two recently published articles report on how translocation of the gut bacterium Enterococcus gallinarum drives autoimmunity in mice and humans, and on the role of other commensal bacteria in triggering immune responses—specifically to the autoantigen Ro60, which…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences